Edition:
United Kingdom

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

9.86USD
18 Jan 2019
Change (% chg)

$0.15 (+1.54%)
Prev Close
$9.71
Open
$9.72
Day's High
$9.87
Day's Low
$9.57
Volume
154,592
Avg. Vol
242,853
52-wk High
$21.69
52-wk Low
$8.04

Latest Key Developments (Source: Significant Developments)

Karyopharm Therapeutics Says Exec VP, CFO And Treasurer Michael Falvey Resigned
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS INC - MICHAEL FALVEY RESIGNED AS EXECUTIVE VP, CFO AND TREASURER OF CO, EFFECTIVE JANUARY 18, 2019 - SEC FILING.KARYOPHARM THERAPEUTICS INC - CAMERON PETERS WILL SERVE AS CO'S PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER, ON AN INTERIM BASIS.  Full Article

Karyopharm's Selinexor Receives FDA "Fast Track" Status For Type Of Lymphoma
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM’S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA.KARYOPHARM THERAPEUTICS INC - FDA HAS ASSIGNED A PRIORITY REVIEW AND GIVEN AN ACTION DATE OF APRIL 6, 2019 UNDER PRESCRIPTION DRUG USER-FEE ACT (PDUFA)..  Full Article

Karyopharm Therapeutics Announces Pricing Of $150 Million Of Convertible Senior Notes
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES PRICING OF $150 MILLION OF CONVERTIBLE SENIOR NOTES.KARYOPHARM THERAPEUTICS INC - PRICING OF $150 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 3.00% CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Karyopharm Therapeutics Announces Proposed Private Offering Of $150 Mln Of Convertible Senior Notes
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PRIVATE OFFERING OF $150 MILLION OF CONVERTIBLE SENIOR NOTES.KARYOPHARM THERAPEUTICS INC - NOTES WILL MATURE ON OCTOBER 15, 2025.KARYOPHARM THERAPEUTICS - INTENDS TO USE NET PROCEEDS TO CONTINUE ESTABLISHING INFRASTRUCTURE TO SUPPORT POTENTIAL COMMERCIAL LAUNCH OF SELINEXOR.KARYOPHARM THERAPEUTICS - TO ALSO USE PROCEEDS FOR CLINICAL TRIALS OF TWO OF CO'S PIPELINE DRUG CANDIDATES IN ONCOLOGY, ELTANEXOR AND KPT-9274.KARYOPHARM THERAPEUTICS - TO ALSO USE NET PROCEEDS TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF SELINEXOR IN HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS.  Full Article

U.S. Food And Drug Administration Accepts Karyopharm’S New Drug Application For Selinexor And Grants Priority Review
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Karyopharm Therapeutics Inc ::U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS KARYOPHARM’S NEW DRUG APPLICATION FOR SELINEXOR AND GRANTS PRIORITY REVIEW.KARYOPHARM THERAPEUTICS INC - PDUFA DATE SET FOR APRIL 6, 2019.KARYOPHARM THERAPEUTICS INC - APPLICATION SEEKS ACCELERATED APPROVAL FOR SELINEXOR AS A TREATMENT FOR PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM - PLANS TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019 WITH REQUEST FOR CONDITIONAL APPROVAL.KARYOPHARM THERAPEUTICS INC - PLANS TO COMMERCIALIZE SELINEXOR IN U.S. AS EARLY AS FIRST HALF OF 2019.  Full Article

Karyopharm Completes Rolling Submission Of New Drug Application To FDA For Selinexor
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR SELINEXOR AS A TREATMENT FOR PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - KARYOPHARM PLANS TO COMMERCIALIZE SELINEXOR IN U..KARYOPHARM THERAPEUTICS- SHOULD APPLICATION BE APPROVED BY FDA, SELINEXOR COULD BECOME AVAILABLE IN H1 2019.KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EMA IN EARLY 2019.  Full Article

Karyopharm Initiates Rolling Submission Of New Drug Application To FDA For Selinexor
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR SELINEXOR AS A TREATMENT FOR PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO COMPLETE SUBMISSION DURING SECOND HALF OF 2018.KARYOPHARM THERAPEUTICS INC - PENDING MARKETING APPROVAL BY FDA, KARYOPHARM PLANS TO COMMERCIALIZE SELINEXOR IN U.S.  Full Article

Karyopharm Therapeutics Files For Potential Mixed Shelf; Size Not Disclosed
Monday, 2 Jul 2018 

July 2 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln
Tuesday, 1 May 2018 

May 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS INC SAYS OFFERING SHARES OF CO'S COMMON STOCK WITH AN AGGREGATE OFFERING PRICE OF $125 MILLION - SEC FILING.  Full Article

Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 1 May 2018 

May 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.COMMENCEMENT OF A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION IN SHARES OF ITS COMMON STOCK.INTENDS TO USE NET PROCEEDS OF OFFERING TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF SELINEXOR.TO USE PROCEEDS OF OFFERING TO CONTINUE ESTABLISHING COMMERCIAL INFRASTRUCTURE FOR POTENTIAL LAUNCH OF SELINEXOR IN U.S..  Full Article